About Medicure

Our Company

Medicure Inc. is a specialty pharmaceutical company focused on the development, commercialization, and distribution of human therapeutics and healthcare products. It primarily targets the United States market. Our vision is to become a leading pharmaceutical company offering a growing portfolio of products that improve patients' lives.

Medicure Inc. Corporate Information

Medicure Inc. is publicly traded on the TSX Venture Exchange under the symbol "MPH" and in the United States on the OTC market under the symbol "MCUJF." Its subsidiaries include Medicure International, Inc. (Barbados), which owns the U.S. rights to AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets; two U.S. corporations, Medicure USA, Inc. and Medicure Pharma, Inc., which distribute the Company's products in the United States; and the Company's pharmacy operations - Marley Drug, Inc., a mail-order and retail pharmacy serving all 50 states, Washington D.C. and Puerto Rico; Gateway Medical Pharmacy in Portland, Oregon; and West Olympia Pharmacy in Olympia, Washington.

Medicure's research and development is focused on MC-1, an investigational therapy being evaluated in the Phase 3 MEND-PNPO trial for the treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency, a rare neurometabolic disorder. MC-1 has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA, and Orphan Drug designation from the EMA.

For more information About Medicure and the risks and uncertainties involved in its business, please refer to the most recent Management Discussion and Analysis and in the "Risk Factors" section of its most recent Form 20F.

Contact Information

Investor Relations
ir@medicure.com